Skip to main content
C

Celestra Inc. — Investor Relations & Filings

Ticker · 352770 ISIN · KR7352770002 KO Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 378 across all filing types
Latest filing 2023-05-08 Major Shareholding Noti…
Country KR South Korea
Listing KO 352770

About Celestra Inc.

https://celestrahealth.com/

Celestra Inc. develops and commercializes digital biomarkers for monitoring neurological conditions. The company's core product is the Celestra Health platform, an FDA-designated Class II medical device that provides quantitative gait analysis for patients in their natural environment. The platform utilizes wearable smart insoles equipped with gyroscopes, accelerometers, and pressure sensors to collect movement data. This data is processed by a cloud-based system using advanced machine learning algorithms to measure over 200 aspects of a patient's gait. The system is designed to detect subtle changes in disease progression for conditions such as Multiple Sclerosis and Parkinson’s Disease earlier than traditional clinical assessments. It offers laboratory-grade accuracy, providing clinicians with actionable insights through a proprietary composite index and enabling pharmaceutical firms to assess drug therapy effectiveness more efficiently.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% rule filing). It details changes in share ownership by a major shareholder (Amicogen, Inc.) in a listed company (Clinomics). This falls under the category of Major Shareholding Notification (MRQ) as it tracks changes in significant share ownership levels.
2023-05-08 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea used when an entity's shareholding in a listed company crosses certain thresholds (typically 5%). This document specifically details the change in shareholding by Amicogen (주) in Clinomics (주) due to market sales. This falls under the category of Major Shareholding Notification.
2023-04-07 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 1% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transaction (disposal of 50,000 shares) by an executive (Cho Su-an) of Clinomics. This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2023-03-30 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 1% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties (directors/executives). This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2023-03-30 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official report of the results of a General Meeting of Shareholders (정기주주총회결과) for Clinomics, dated 2023-03-28. It details the approval of financial statements, dividend resolutions, and the election of directors and auditors. This falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides the official outcome of shareholder votes.
2023-03-28 Korean
대표이사변경
Board/Management Information Classification · 1% confidence The document is a formal announcement regarding a change in the company's representative directors (CEO). It explicitly lists the 'before' and 'after' names of the representative directors, the reason for the change (management efficiency), and the date of the board resolution. This falls directly under the category of board/management changes.
2023-03-28 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.